IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v38y2018i1p26-33.html
   My bibliography  Save this article

Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size

Author

Listed:
  • Kelvin K. W. Chan
  • Feng Xie
  • Andrew R. Willan
  • Eleanor M. Pullenayegum

Abstract

Background. Resource-constrained countries have difficulty conducting large EQ-5D valuation studies, which limits their ability to conduct cost-utility analyses using a value set specific to their own population. When estimates of similar but related parameters are available, shrinkage estimators reduce uncertainty and yield estimators with smaller mean square error (MSE). We hypothesized that health utilities based on shrinkage estimators can reduce MSE and mean absolute error (MAE) when compared to country-specific health utilities. Methods. We conducted a simulation study (1,000 iterations) based on the observed means and standard deviations (or standard errors) of the EQ-5D-3L valuation studies from 14 counties. In each iteration, the simulated data were fitted with the model based on the country-specific functional form of the scoring algorithm to create country-specific health utilities (“naïve†estimators). Shrinkage estimators were calculated based on the empirical Bayes estimation methods. The performance of shrinkage estimators was compared with those of the naïve estimators over a range of different sample sizes based on MSE, MAE, mean bias, standard errors and the width of confidence intervals. Results. The MSE of the shrinkage estimators was smaller than the MSE of the naïve estimators on average, as theoretically predicted. Importantly, the MAE of the shrinkage estimators was also smaller than the MAE of the naïve estimators on average. In addition, the reduction in MSE with the use of shrinkage estimators did not substantially increase bias. The degree of reduction in uncertainty by shrinkage estimators is most apparent in valuation studies with small sample size. Conclusion. Health utilities derived from shrinkage estimation allow valuation studies with small sample size to “borrow strength†from other valuation studies to reduce uncertainty.

Suggested Citation

  • Kelvin K. W. Chan & Feng Xie & Andrew R. Willan & Eleanor M. Pullenayegum, 2018. "Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size," Medical Decision Making, , vol. 38(1), pages 26-33, January.
  • Handle: RePEc:sae:medema:v:38:y:2018:i:1:p:26-33
    DOI: 10.1177/0272989X17725748
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X17725748
    Download Restriction: no

    File URL: https://libkey.io/10.1177/0272989X17725748?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Aki Tsuchiya & Shunya Ikeda & Naoki Ikegami & Shuzo Nishimura & Ikuro Sakai & Takashi Fukuda & Chisato Hamashima & Akinori Hisashige & Makoto Tamura, 2002. "Estimating an EQ‐5D population value set: the case of Japan," Health Economics, John Wiley & Sons, Ltd., vol. 11(4), pages 341-353, June.
    2. Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch, 2004. "Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 461-475, May.
    3. Andrew R. Willan & Eleanor M. Pinto & Bernie J. O'Brien & Padma Kaul & Ron Goeree & Larry Lynd & Paul W. Armstrong, 2005. "Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT‐3 economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 327-338, April.
    4. L. M. Lamers & J. McDonnell & P. F. M. Stalmeier & P. F. M. Krabbe & J. J. V. Busschbach, 2006. "The Dutch tariff: results and arguments for an effective design for national EQ‐5D valuation studies," Health Economics, John Wiley & Sons, Ltd., vol. 15(10), pages 1121-1132, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Samer A. Kharroubi & Yara Beyh, 2021. "Bayesian modeling of health state preferences: could borrowing strength from existing countries’ valuations produce better estimates," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 773-788, July.
    2. Samer A. Kharroubi, 2021. "Modeling SF-6D Health Utilities: Is Bayesian Approach Appropriate?," IJERPH, MDPI, vol. 18(16), pages 1-14, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mathieu F. Janssen & Ines Buchholz & Dominik Golicki & Gouke J. Bonsel, 2022. "Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries," PharmacoEconomics, Springer, vol. 40(11), pages 1081-1093, November.
    2. Munir A. Khan & Jeff Richardson, 2019. "Is the Validity of Cost Utility Analysis Improved When Utility is Measured by an Instrument with ‘Home-Country’ Weights? Evidence from Six Western Countries," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 145(1), pages 1-15, August.
    3. Mathieu F. Janssen & Gouke J. Bonsel & Nan Luo, 2018. "Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries," PharmacoEconomics, Springer, vol. 36(6), pages 675-697, June.
    4. Irina Cleemput, 2010. "A social preference valuations set for EQ-5D health states in Flanders, Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 205-213, April.
    5. Julie Chevalier & Gérard Pouvourville, 2013. "Valuing EQ-5D using Time Trade-Off in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 57-66, February.
    6. Eleanor Pullenayegum & Kuhan Perampaladas & Kathryn Gaebel & Brett Doble & Feng Xie, 2015. "Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(8), pages 847-855, November.
    7. Nan Luo & Pei Wang & Julian Thumboo & Yee-Wei Lim & Hubertus Vrijhoef, 2014. "Valuation of EQ-5D-3L Health States in Singapore: Modeling of Time Trade-Off Values for 80 Empirically Observed Health States," PharmacoEconomics, Springer, vol. 32(5), pages 495-507, May.
    8. Andrea Manca & Paul C. Lambert & Mark Sculpher & Nigel Rice, 2007. "Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling," Medical Decision Making, , vol. 27(4), pages 471-490, July.
    9. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2012. "Using a discrete choice experiment to estimate health state utility values," Journal of Health Economics, Elsevier, vol. 31(1), pages 306-318.
    10. Méndez, Ildefonso & Abellán Perpiñán, Jose M. & Sánchez Martínez, Fernando I. & Martínez Pérez, Jorge E., 2011. "Inverse probability weighted estimation of social tariffs: An illustration using the SF-6D value sets," Journal of Health Economics, Elsevier, vol. 30(6), pages 1280-1292.
    11. Samer A. Kharroubi & Yara Beyh & Marwa Diab El Harake & Dalia Dawoud & Donna Rowen & John Brazier, 2020. "Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population," IJERPH, MDPI, vol. 17(3), pages 1-15, February.
    12. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
    13. Attema, Arthur E. & Brouwer, Werner B.F., 2012. "A test of independence of discounting from quality of life," Journal of Health Economics, Elsevier, vol. 31(1), pages 22-34.
    14. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    15. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
    16. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.
    17. Jasjeet Singh Sekhon & Richard D. Grieve, 2012. "A matching method for improving covariate balance in cost‐effectiveness analyses," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 695-714, June.
    18. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.
    19. Rachael Hunter & Gianluca Baio & Thomas Butt & Stephen Morris & Jeff Round & Nick Freemantle, 2015. "An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 33(4), pages 355-366, April.
    20. Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny, 2015. "A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)," PharmacoEconomics, Springer, vol. 33(8), pages 867-877, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:38:y:2018:i:1:p:26-33. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.